Arcutis Biotherapeutics (ARQT) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARQT shares.
View ARQT analyst ratings or view top-rated stocks.

6 analysts have issued twelve-month target prices for Arcutis Biotherapeutics' stock. Their ARQT share price forecasts range from $22.00 to $57.00. On average, they expect the company's stock price to reach $43.43 in the next twelve months. This suggests a possible upside of 717.9% from the stock's current price.
View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts.

Arcutis Biotherapeutics' stock was trading at $14.80 at the start of the year. Since then, ARQT shares have decreased by 64.1% and is now trading at $5.31.
View the best growth stocks for 2023 here.

Arcutis Biotherapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 13,280,000 shares, an increase of 6.4% from the August 31st total of 12,480,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is presently 13.1 days. Approximately 29.7% of the shares of the stock are sold short.
View Arcutis Biotherapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ARQT earnings forecast.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.22) by $0.06. The company had revenue of $5.19 million for the quarter, compared to analyst estimates of $4.87 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 188.88% and a negative net margin of 2,837.94%.

Virtus LifeSci Biotech Clinical Trials ETF holds 10,172 shares of ARQT stock, representing 0.89% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

(ARQT) raised $125 million in an initial public offering on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARQT stock can currently be purchased for approximately $5.31.

Arcutis Biotherapeutics (NASDAQ:ARQT) has a market capitalization of $327.36 million and generates $3.69 million in revenue each year. The company earns $-311,460,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis.

The company employs 268 workers across the globe.

Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The official website for the company is www.arcutis.com. The company can be reached via phone at 805-418-5006 or via email at ir@arcutis.com.